DDInter1766 DDInter1082
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA in January 2020 for the treatment of TED. Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Teprotumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Teprotumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Teprotumumab may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Teprotumumab may cause a moderate interaction that could exacerbate diseases when taken with Glipizide